- Trial phase
- Approved
- Time to market
- Already approved and commercially available (FDA approved May 28, 2021). A pediatric label expansion, if supported by the ENLIGHTEN-Youth trial, would be a supplemental approval, typically 6-12 months after data submission.
- Why 4/10
- LYBALVI is already FDA-approved and commercially marketed with no pending regulatory decision. The next hard catalyst is topline data from the ENLIGHTEN-Youth Phase 3 pediatric trial (primary completion Sep 2026, results not yet reported as of Nov 4, 2026), but this is not a dated binary event. LYBALVI is one of four marketed products at Alkermes (alongside VIVITROL, ARISTADA, and LUMRYZ), so it is not a single-asset binary. ImpactScore of 4 reflects an approved drug with commercial momentum but no imminent regulatory binary.
Watch for topline results from the ENLIGHTEN-Youth Phase 3 pediatric trial (primary completion Sep 2026, results unreported as of Nov 4). Positive data could support a label expansion into adolescents, opening a new patient segment. Separately, LYBALVI's expanded payer access (~80% of covered lives) should drive prescription volume growth into 2027, though gross-to-net adjustments are expected to rise to ~45%.
Price Chart
Executive Summary
LYBALVI (olanzapine and samidorphan) is an FDA-approved oral atypical antipsychotic from Alkermes plc (Nasdaq: ALKS) for adults with schizophrenia and bipolar I disorder. Its key differentiator is samidorphan, which mitigates the weight gain that olanzapine alone typically causes. Approved in May 2021, LYBALVI generated $95.9M in Q3 2026 net sales (18% prescription growth YoY) and $346.7M in full-year 2025. The drug faces a crowded competitive field of newer antipsychotics (Caplyta, Vraylar, Rexulti) and generic olanzapine. A Phase 3 pediatric trial (ENLIGHTEN-Youth) with primary completion in September 2026 could support label expansion into adolescents, but results have not yet been reported. LYBALVI is one of four marketed products at Alkermes, which also has a pipeline of orexin 2 receptor agonists. Analyst consensus is bullish (20 Buy/Strong Buy, mean PT $56.21), but the stock faces near-term headwinds from rising gross-to-net adjustments and elevated short volume.
How It Works
LYBALVI combines two drugs in one pill: olanzapine, a standard atypical antipsychotic that controls schizophrenia and bipolar symptoms by blocking dopamine and serotonin receptors, and samidorphan, which blocks opioid receptors to counteract the weight gain and metabolic side effects that olanzapine typically causes. Clinical trials show patients on LYBALVI gain about 37-50% less weight than those on olanzapine alone.
Trial Status
LYBALVI is FDA-approved and commercially marketed for adults with schizophrenia and bipolar I disorder. A Phase 3 pediatric trial (ENLIGHTEN-Youth, NCT05303064) comparing LYBALVI to olanzapine in adolescents (schizophrenia ages 13-17, bipolar I ages 10-17) had a primary completion date of September 2026; topline results have not been announced as of November 4, 2026. Long-term open-label extension data through four years has been previously reported showing sustained safety and efficacy.
The Two-Sided Case
Upcoming Catalysts
- ENLIGHTEN-Youth Phase 3 pediatric trial topline results (primary completion Sep 2026, results pending)
- Potential sNDA submission for pediatric label expansion if ENLIGHTEN-Youth is positive
- LYBALVI prescription volume acceleration as expanded payer access (~80% of covered lives) matures through 2027
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Alkermes plc. 8-K ALKS ·Originating report